Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in CAR-T Therapy: a Randomized Trial

NCT07593482 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07593482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07593482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in CAR-T Therapy: a Randomized Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
September 14, 2026
Completion date
March 31, 2030
Enrollment
92 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma